The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -236,928 |
| Stock-based compensation | 29,876 |
| Non-cash operating lease expense | 1,892 |
| Depreciation and amortization | 208 |
| Net accretion of investments in marketable securities | 2,934 |
| Impairment of held for sale assets | 595 |
| Loss on disposal of property and equipment | -47 |
| Amortization of debt issuance costs and accretion of final payment fee | 492 |
| Amortization and write-off of deferred debt issuance costs | 717 |
| Other noncash expenses | 32 |
| Prepaid expenses and other current assets | 2,770 |
| Accounts payable | 71 |
| Accrued liabilities | 4,195 |
| Operating lease liabilities | -1,880 |
| Other assets | 53 |
| Net cash used in operating activities | -206,440 |
| Purchases of marketable securities | 82,868 |
| Cash paid for acquisition of assets | 0 |
| Proceeds from maturities of marketable securities | 251,170 |
| Proceeds from sale of property and equipment | 218 |
| Net cash provided by (used in) investing activities | 168,520 |
| Proceeds from term loan, net | 57,161 |
| Proceeds from exercise of stock options | 0 |
| Proceeds from employee stock purchase plan purchases | 275 |
| Proceeds from issuance of common stock in at-the-market transactions, net of commissions and offering costs | 19,653 |
| Net cash provided by financing activities | 77,089 |
| Net change in cash and cash equivalents and restricted cash | 39,169 |
| Cash and cash equivalents and restricted cash at beginning of year | 143,361 |
| Cash and cash equivalents and restricted cash at end of period | 182,530 |
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA)